Pace Of Bristol-Myers Squibb Company' Combo Cancer Trial Spooks Investors

Published: Jan 28, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Bristol-Myers Squibb Co (BMY.N) on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.

The stock dropped as much as 6.7 percent after company officials said on a conference call with investors that they were not yet planning a late-stage trial that would combine two of its high-profile drugs as a treatment for lung cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news